Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study Authors
First Online: 11 November 2012 DOI:
Cite this article as: Krishnan, A., Wickersham, J.A., Chitsaz, E. et al. AIDS Behav (2013) 17: 171. doi:10.1007/s10461-012-0362-3 Abstract
HIV-infected individuals with substance use disorders have a high prevalence of medical and psychiatric morbidities that complicate treatment. Incarceration further disrupts healthcare access and utilization. Without appropriate diagnosis and treatment, drug relapse upon release exceeds 85 %, which contributes to poor health outcomes. A prospective cohort of 1,032 HIV-infected jail detainees were surveyed in a ten-site demonstration project during incarceration and six-months post-release, in order to examine the effect of predisposing factors, enabling resources and need factors on their subsequent drug use. Homelessness, pre-incarceration cocaine and opioid use, and high drug and alcohol severity were significantly associated with cocaine and opioid relapse. Substance abuse treatment, though poorly defined, did not influence post-release cocaine and opioid use. An approach that integrates multiple services, simultaneously using evidence-based substance abuse, psychiatric care, and social services is needed to improve healthcare outcomes for HIV-infected persons transitioning from jails to the community.
Keywords HIV/AIDS Substance use disorders Jail detainees Substance abuse treatment Addiction severity Heroin Cocaine Homelessness References
Sabol WJ, Minton TD. Jail inmates at midyear 2007. DC: Washington; 2008.
West H, Sabol W. Prisoners in 2007. Washington, DC: Bureau of Justice Statistics Bulletin (NCJ224280); 2008.
Warren J, Gelb A, Horowitz J, Riordan J. One in 100: behind bars in America 2008. Washington, DC: The Pew Charitable Trusts, Public Safety Performance Project; 2008.
Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS ONE. 2009;4(11):e7558.
Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92(11):1789–94.
Fazel S, Baillargeon J. The health of prisoners. Lancet. 2011;377:956–65.
Schwarcz SK, Hsu LC, Vittinghoff E, Vu A, Bamberger JD, Katz MH. Impact of housing on the survival of persons with AIDS. BMC Public Health. 2009;9:220.
Williams BA, McGuire J, Lindsay RG, et al. Coming home: health status and homelessness risk of older pre-release prisoners. J Gen Intern Med. 2010;25(10):1038–44.
Springer SA, Spaulding AC, Meyer JP, Altice FL. Public health implications of adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis. 2011;53(5):469–79.
Baillargeon J, Giordano TP, Rich JD, et al. Accessing antiretroviral therapy following release from prison. JAMA. 2009;301(8):848–57.
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38(12):1754–60.
Stephenson BL, Wohl DA, Golin CE, Tien HC, Stewart P, Kaplan AH. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep. 2005;120(1):84–8.
Stephenson BL, Wohl DA, McKaig R, et al. Sexual behaviours of HIV-seropositive men and women following release from prison. Int J STD AIDS. 2006;17(2):103–8.
MacGowan RJ, Margolis A, Gaiter J, et al. Predictors of risky sex of young men after release from prison. Int J STD AIDS. 2003;14(8):519–23.
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.
Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251–9.
Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.
Gonzalez A, Barinas J, O’Cleirigh C. Substance use: impact on adherence and HIV medical treatment. Curr HIV/AIDS Rep. 2011;8(4):223–34.
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months post release. J Subst Abuse Treat. 2009;37(3):277–85.
Braithwaite RL, Arriola KR. Male prisoners and HIV prevention: a call for action ignored. Am J Public Health. 2003;93(5):759–63.
Chen NE, Meyer JP, Avery AK, et al. Adherence to HIV treatment and care among previously homeless jail detainees. AIDS Behav. 2011. doi:
Flanigan TP, Zaller N, Beckwith CG, et al. Testing for HIV, sexually transmitted infections, and viral hepatitis in jails: still a missed opportunity for public health and HIV prevention. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S78–83.
de Voux A, Spaulding AC, Beckwith C, et al. Early identification of HIV: Empirical support for jail-based screening. PLoS ONE. 2012;7(5):e37603.
White MC, Tulsky JP, Estes M, Jamison R, Long HL. Health and health behaviors in HIV-infected jail inmates, 1999 and 2005. AIDS Patient Care STDS. 2008;22(3):221–31.
Draine J, Ahuja D, Altice FL, et al. Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care. 2011;23(3):366–77.
Althoff AL, Zelenev AL, Meyer JP, et al. Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav. 2012. doi:
Office of National Drug Control Policy. ADAM II: 2011 Annual Report, Arrestee Drug Abuse Monitoring Program. Washington, DC: Office of National Drug Control Policy. May 2010.
Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10.
Gelberg L, Andersen RM, Leake BD. The Behavioral Model for Vulnerable Populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000;34(6):1273–302.
McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):14.
Rikoon SH, Cacciola JS, Carise D, Alterman AI, McLellan AT. Predicting DSM-IV dependence diagnoses from Addiction Severity Index composite scores. J Subst Abuse Treat. 2006;31(1):17–24.
Calsyn DA, Saxon AJ, Bush KR, et al. The Addiction Severity Index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity. Drug Alcohol Depend. 2004;76(2):165–71.
McLellan AT, Cacciola JC, Alterman AI, Rikoon SH, Carise D. The Addiction Severity Index at 25: origins, contributions and transitions. American Journal of Addiction. 2006;15(2):11.
James JD, editor. Profile of jail inmates, 2002. Washington, DC: U.S. Department of Justice; 2004.
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One. 2012;7(5).
Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health. 2010;87(4):592–602.
Friedmann PD, Hoskinson R, Gordon M, et al. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33(1):9–18.
Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1–2):83–8.
Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2011;112(3):15.
Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22–32.
Maslow AH. Toward a Pschology of Being. 3rd ed. New York: John Wiley and Sons; 1998.
Wolitski RJ, Kidder DP, Pals SL, et al. Randomized trial of the effects of housing assistance on the health and risk behaviors of homeless and unstably housed people living with HIV. AIDS Behav. 2010;14(3):493–503.
Gelberg L, Gallagher TC, Andersen RM, Koegel P. Competing priorities as a barrier to medical care among homeless adults in Los Angeles. Am J Public Health. 1997;87(2):217–20.
Harris A, Selling D, Luther C, et al. Rate of community methadone treatment reporting at jail reentry following a methadone increased dose quality improvement effort. Subst Abus. 2012;33(1):70–5.
Centers for Disease Control and Prevention. HIV Testing Implementation Guidance for Correctional Settings; January 2009. p. 1–38. Available at:
Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA. 2012;307(12):1259–60.
Mermin J, Fenton KA. The future of HIV prevention in the United States. JAMA. 2012;308(4):347–8.
PubMed CrossRef Copyright information
© Springer Science+Business Media New York 2012